Related Experiment Video
Updated: Jul 4, 2025

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
Published on: February 16, 2024
Predicting Factors of Long-term Outcome of Gastrointestinal Behçet's Disease: A Chinese Retrospective Study
Xiaoman Zu1, Shanshan Xiong1, Yaming Lu1
1Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Insights
Gastrointestinal Behçet's disease (BD) requires long-term treatment for mucosal healing. Ulcer size and location significantly impact healing outcomes in patients with gastrointestinal BD.
Area of Science:
- Gastroenterology
- Immunology
- Internal Medicine
Background:
- Behçet's disease (BD) is a multisystemic inflammatory disorder.
- Gastrointestinal involvement in BD is complex and not fully understood.
- Identifying factors influencing long-term outcomes in gastrointestinal BD is crucial for patient management.
Purpose of the Study:
- To identify factors influencing the long-term outcomes of patients with gastrointestinal Behçet's disease.
- To evaluate mucosal healing and surgical rates in gastrointestinal BD.
- To determine predictors of mucosal healing in this patient population.
Main Methods:
- Retrospective analysis of consecutive gastrointestinal BD patients.
- Data collection included demographics, symptoms, endoscopic findings, treatments, and surgical history.
- Kaplan-Meier curves, log-rank tests, and Cox regression models were used to assess outcomes and influencing factors.
Main Results:
- 175 patients with gastrointestinal BD were analyzed; common symptoms included oral ulcers and abdominal pain.
- Cumulative surgical rates were 8.6% at 1 year and 9.1% at 5 years.
- Cumulative mucosal healing rates reached 61.4% at 5 years; mono-immunosuppressant therapy showed earlier healing than combined or escalation therapies.
- Moderate to severe disease activity, maximal ulcer diameter >4 cm, and nonsimple esophageal involvement were risk factors for mucosal healing.
- Nonsimple esophageal involvement and maximal ulcer diameter >4 cm were identified as independent risk factors for mucosal healing.
Conclusions:
- Long-term treatment is generally required for achieving mucosal healing in gastrointestinal BD.
- The characteristics of gastrointestinal ulcers, specifically their location and size, significantly affect mucosal healing.
- Understanding these factors can guide treatment strategies and improve long-term management of gastrointestinal BD.
Purpose:
Behçet's disease (BD) is a complex disorder affecting multiple systems and organs, and gastrointestinal BD is poorly understood. We aimed to identify factors influencing the long-term outcomes of patients with gastrointestinal BD.
Methods:
Consecutive patients with gastrointestinal BD were analyzed retrospectively. Data on the following clinical characteristics were collected: sex, age at diagnosis, symptoms, endoscopic findings, medical treatments, and surgery. Mucosal healing and surgical rates at 1, 2, and 5 years were evaluated. Log-rank test and Cox proportional hazards regression models were used to evaluate the factors affecting long-term outcomes.
Findings:
Baseline data of 175 patients with gastrointestinal BD were included. The mean (SD) age at diagnosis was 38.3 (12.9) years. The typical clinical symptoms were oral ulcer (72.6%), abdominal pain (71.4%), and weight loss (41.1%). The most commonly involved location was the ileocecum; isolated oval ulcer was the most common ulcer type. Seventeen patients (9.7%) underwent 18 surgeries after inclusion. The cumulative surgical rates were 8.6% (n/N = 15/175), 8.6% (n/N = 15/175), and 9.1% (n/N = 16/175) in 1, 2, and 5 years, respectively. Data from 101 patients who underwent at least 2 endoscopies were included in the analysis for mucosal healing. Kaplan-Meier curve showed that the cumulative mucosal healing rates at 1, 2, and 5 years were 34.7% (n/N = 35/101), 41.6% (n/N = 42/101), and 61.4% (n/N = 62/101), respectively. We compared cumulative mucosal healing rates between 4 treatment groups, including 5-aminosalicylic acid (3% [n/N = 3/101]), mono-immunosuppressant (31.7% [n/N = 32/101]), combined therapy (36.6% [n/N = 37/101]), and escalation therapy (28.7% [n/N = 29/101]), and found that mono-immunosuppressant achieved earlier mucosal healing than combined therapy (P = 0.0008) and escalation therapy (P = 0.0008). The univariate analysis showed that moderate to severe disease activity (P = 0.013, P = 0.004), diameter of the maximal ulcer >4 cm (P = 0.002), and nonsimple esophageal involvement (P < 0.001) were risk factors, and number of ulcers between 2 and 5 was the protective factor of mucosal healing (P = 0.001). Multivariate regression analysis indicated that nonsimple esophageal involvement (P < 0.001) and the maximal ulcer >4 cm (P = 0.041) were independent risk factors of mucosal healing.
Implications:
Most patients with gastrointestinal BD need long-term treatment to achieve mucosal healing. The location and size of ulcers have a significant impact on the mucosal healing of gastrointestinal BD.
Related Concept Videos
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

